GLP-1s
Article
What’s on the horizon for nonalcoholic steatohepatitis (NASH) treatment?
The future of NASH treatment is more promising than ever with improved methods for diagnosis and new drugs in development.
Read More
Article
GLP-1s and digital support: A winning combination
When GLP-1s aren’t enough, lifestyle modification can be key to weight management.
Read More
Article
Easing the impact of GLP-1s
With GLP-1 sales forecast to exceed $100 billion, plan sponsors need the tools to control growth and expand access.
Read More
Article
A plan sponsor’s guide to GLP-1 medications for weight loss
GLP-1 medications are FDA-approved specifically for weight loss for more than half the adult population of the United States. Plan sponsors can take action to manage weight and other cardiodiabesity-r...
Read More